Inclusion Criteria:

• Histologically or cytologically confirmed epithelial ovarian carcinoma. Patients with fallopian or peritoneal cancer will also be eligible.
• Patients with any solid tumor that may be treated with weekly paclitaxel will be eligible for the phase 1 portion.
• For the phase 2 portion, patients must have elevated CA125 levels evaluable/assessable according to GCIG criteria (ie, > 70 U/mL) documented by 2 measurements at least 1 week apart [30 ].
• Patients must have progressive disease as documented by a doubling of CA125 or by RECIST criteria.
• Age >= 18 years.
• ECOG PS 0 -1
• Predicted life expectancy >= 12 weeks.
• Patients may have had prior therapy, providing the following conditions are met:
• Chemotherapy: Prior chemotherapy must have been completed at least 3 weeks prior to study enrollment (6 weeks for mitomycin C, nitrosoureas or high-dose carboplatin [>= 600 mg/m²]
• and 4 weeks for investigational drugs) and the patient should have recovered from any drug-related toxicities (with the exception of grade 1 neuropathy and or alopecia).
• Phase 1: While there is no limit on the number of prior regimens for patients entered into the phase 1 portion, any prior taxane therapy must have been administered on a 3 week schedule.
• Phase 2: Patients must have received prior chemotherapy, which must have contained a platinum and a taxane at some point. Any prior taxane therapy must have been administered on a 3 week schedule.
• A maximum of 2 prior chemotherapy regimens are permitted. Patients must be refractory (PD during chemotherapy) or resistant (PD within six months of completing chemotherapy) to their last platinum-containing chemotherapy regimen.
• Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration/randomization.
• A minimum of 21 days must have elapsed between the end of radiotherapy and registration/randomization into the study unless the radiation affected less than 25% of bone marrow.
• Surgery: Previous surgery is permitted provided that adequate wound healing has occurred prior to registration/randomization.
• Fasting glucose <= 150 mg/dL (8.3 mmol/L).
• Adequate hematopoietic, hepatic, and renal function defined as follows:
• Neutrophil count > = 1.5 x 10 ^9 /L and platelet count > = 100 x 10^9/L;
• Bilirubin <= 1.5 x ULN;
• AST and/or ALT <= 2.5 x ULN or < = 5 x ULN if patient has documented liver metastases; and
• Serum creatinine < = 1.5 x ULN.
• Patients, both males and females, with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective contraceptive measures.
• measures (ie, barrier methods that include condom or diaphragm, with spermicide) throughout the study.
• Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration/randomization.
• Patients must provide verbal and written informed consent to participate in the study.

Exclusion Criteria:

• Diabetes mellitus currently requiring medication (eg, insulin or oral hypoglycemics).
• During the phase 2 portion, patients with histology of abdominal adenocarcinoma of unknown origin or a diagnosis of a borderline ovarian tumor.
• Previous or concurrent malignancies (excluding curatively treated basal or squamous cell carcinoma of the skin or cervical cancer) unless the patient has been in remission for at least 3 years.
• History of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease;
• QTc interval > 450 msec at baseline; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse
• (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea).
• History of cerebrovascular accident (CVA) within 6 months prior to registration/randomization or that is not stable.
• Prior therapy with an IGF1R inhibitor.
• Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing.
• Known or prior hypersensitivity to taxanes or drugs containing Cremophor.
• Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation,
• active peptic ulcer or prior surgical procedures or bowel resection affecting absorption.
• Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to registration/randomization) that would impair the ability of the patient to receive protocol treatment.
• History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent.
• Pregnancy or breast-feeding.
• Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to registration/randomization.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug.